Genmab As Stock Book Value Per Share
| GNMSF Stock | USD 196.00 0.36 0.18% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab A/S's financial success or failures. It also enables traders to predict the movement of Genmab Pink Sheet. The fundamental analysis module provides a way to measure Genmab A/S's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab A/S pink sheet.
Genmab |
Genmab AS Company Book Value Per Share Analysis
Genmab A/S's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Genmab A/S Book Value Per Share | 408.67 X |
Most of Genmab A/S's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Genmab AS is about 408 times. This is 24139.12% lower than that of the Healthcare sector and 264.37% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 78.84% higher than that of the company.
Genmab Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab A/S's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genmab A/S could also be used in its relative valuation, which is a method of valuing Genmab A/S by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in book value per share category among its peers.
Genmab Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 26.41 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 39.08 X | |||
| Price To Book | 7.94 X | |||
| Price To Sales | 2.45 X | |||
| Revenue | 8.48 B | |||
| Gross Profit | 8.48 B | |||
| EBITDA | 4.24 B | |||
| Net Income | 3.01 B | |||
| Cash And Equivalents | 21.61 B | |||
| Cash Per Share | 330.53 X | |||
| Total Debt | 634 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 13.11 X | |||
| Book Value Per Share | 408.67 X | |||
| Cash Flow From Operations | 2.23 B | |||
| Earnings Per Share | 12.00 X | |||
| Price To Earnings To Growth | 1.20 X | |||
| Target Price | 383.57 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.67 | |||
| Market Capitalization | 26.78 B | |||
| Total Asset | 24.63 B | |||
| Retained Earnings | (3.96 B) | |||
| Working Capital | 3.72 B | |||
| Current Asset | 4.14 B | |||
| Current Liabilities | 419 M | |||
| Z Score | 25.2 | |||
| Net Asset | 24.63 B |
About Genmab A/S Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..